← All trials
NCT03038230
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2016
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Merus LabsLead sponsor
- B&C Group (Belgium)Collaborator
- LGC LimitedCollaborator
- EurofinsCollaborator
- Kinesis PharmaCollaborator
- Free University of AmsterdamCollaborator
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.